Panacos Pharmaceuticals to Present at Deutsche Bank's 31st Annual Health Care Conference

Strategic Insights -

Panacos Pharmaceuticals, a biotechnology company focused on developing next-generation antiviral products, will present at the Deutsche Bank's 31st Annual Health Care Conference in Boston, Massachusetts, on May 2-3, 2006. Dr. Samuel Ackerman, President and CEO, will deliver a corporate overview on May 2 at 9:45 a.m. EDT. The presentation will be webcast on the company's website, accessible for 30 days.

Key Takeaways:

  • Panacos Pharmaceuticals is developing the next generation of anti-infective products through the discovery and development of small molecule oral drugs for HIV and other major human viral diseases.
  • The company's lead candidate, PA-457, is a maturation inhibitor, a novel class of oral HIV therapeutics discovered by Panacos scientists and their academic collaborators.
  • PA-457 targets a novel step in the virus life cycle, designed to have potent activity against a broad range of HIV, including strains resistant to existing classes of drugs.
  • Drug resistance is the most pressing problem in HIV therapy, and Panacos' proprietary discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion.
  • The company has a Phase 2b study of PA-457 in development, and Panacos is working to progress PA-457's clinical development.

Statistics:

  • The company will present at Deutsche Bank's 31st Annual Health Care Conference on May 2-3, 2006.
  • The presentation will be webcast on the company's website for 30 days.
  • PA-457 is a maturation inhibitor, a novel class of oral HIV therapeutics.
  • PA-457 targets a novel step in the virus life cycle, with potent activity against a broad range of HIV, including strains resistant to existing classes of drugs.